These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

319 related articles for article (PubMed ID: 24650154)

  • 41. Symptom relief in Parkinson disease by safinamide: Biochemical and clinical evidence of efficacy beyond MAO-B inhibition.
    Stocchi F; Vacca L; Grassini P; De Pandis MF; Battaglia G; Cattaneo C; Fariello RG
    Neurology; 2006 Oct; 67(7 Suppl 2):S24-9. PubMed ID: 17030737
    [TBL] [Abstract][Full Text] [Related]  

  • 42. [Safinamide Mesilate (Equfina
    Koebisu M; Ishida T
    Nihon Yakurigaku Zasshi; 2020; 155(4):269-276. PubMed ID: 32612042
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Long-Term Effects of Safinamide on Mood Fluctuations in Parkinson's Disease.
    Cattaneo C; Müller T; Bonizzoni E; Lazzeri G; Kottakis I; Keywood C
    J Parkinsons Dis; 2017; 7(4):629-634. PubMed ID: 28777756
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Clinical implications of irregular ADMET properties with levodopa and other antiparkinson's drugs.
    Dézsi L; Vécsei L
    Expert Opin Drug Metab Toxicol; 2014 Mar; 10(3):409-24. PubMed ID: 24437461
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Treatment of Parkinson's Disease by MAO-B Inhibitors, New Therapies and Future Challenges - A Mini-Review.
    Parambi DGT
    Comb Chem High Throughput Screen; 2020; 23(9):847-861. PubMed ID: 32238135
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Effects of safinamide on non-motor, cognitive, and behavioral symptoms in fluctuating Parkinson's disease patients: a prospective longitudinal study.
    De Micco R; Satolli S; Siciliano M; De Mase A; Giordano A; Tedeschi G; Tessitore A
    Neurol Sci; 2022 Jan; 43(1):357-364. PubMed ID: 34031800
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Safinamide in the treatment of Parkinson's disease.
    Müller T
    Neurodegener Dis Manag; 2020 Aug; 10(4):195-204. PubMed ID: 32648512
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Discovery of novel and potent safinamide-based derivatives as highly selective hMAO-B inhibitors for treatment of Parkinson's disease (PD): Design, synthesis, in vitro, in vivo and in silico biological studies.
    Elkamhawy A; Paik S; Park JH; Kim HJ; Hassan AHE; Lee K; Park KD; Roh EJ
    Bioorg Chem; 2021 Oct; 115():105233. PubMed ID: 34390968
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Computational Fragment-Based Design Facilitates Discovery of Potent and Selective Monoamine Oxidase-B (MAO-B) Inhibitor.
    Jin CF; Wang ZZ; Chen KZ; Xu TF; Hao GF
    J Med Chem; 2020 Dec; 63(23):15021-15036. PubMed ID: 33210537
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Spanish expert consensus on the use of safinamide in Parkinson's disease.
    Valldeoriola F; Grandas F; Arbelo JM; Blázquez Estrada M; Calopa Garriga M; Campos-Arillo VM; Garcia Ruiz PJ; Gómez Esteban JC; Leiva Santana C; Martínez Castrillo JC; Mir P; Salvador Aliaga A; Vivancos Matellano F; Yáñez Baña RM
    Neurologia (Engl Ed); 2021; 36(9):666-672. PubMed ID: 34752344
    [TBL] [Abstract][Full Text] [Related]  

  • 51. The role of glutamatergic neurotransmission in the motor and non-motor symptoms in Parkinson's disease: Clinical cases and a review of the literature.
    Pagonabarraga J; Tinazzi M; Caccia C; Jost WH
    J Clin Neurosci; 2021 Aug; 90():178-183. PubMed ID: 34275546
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Safinamide as an adjunct therapy in older patients with Parkinson's disease: a retrospective study.
    Lo Monaco MR; Petracca M; Vetrano DL; Di Stasio E; Fusco D; Ricciardi D; Laudisio A; Zuccalà G; Onder G; Bentivoglio AR
    Aging Clin Exp Res; 2020 Jul; 32(7):1369-1373. PubMed ID: 31981101
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Switch from rasagiline to safinamide in fluctuating Parkinson's disease patients: a retrospective, pilot study.
    Bianchini E; Sforza M; Rinaldi D; Alborghetti M; De Carolis L; Della Gatta F; Pontieri FE
    Neurol Res; 2021 Nov; 43(11):950-954. PubMed ID: 34142645
    [TBL] [Abstract][Full Text] [Related]  

  • 54. The Role of Monoamine Oxidase B Inhibitors in the Treatment of Parkinson's Disease - An Update.
    Chew ZX; Lim CL; Ng KY; Chye SM; Ling APK; Koh RY
    CNS Neurol Disord Drug Targets; 2023; 22(3):329-352. PubMed ID: 34970960
    [TBL] [Abstract][Full Text] [Related]  

  • 55. The effects of safinamide on dysphagia in Parkinson's disease.
    Hirano M; Samukawa M; Isono C; Nagai Y
    PLoS One; 2023; 18(5):e0286066. PubMed ID: 37228084
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Efficacy of safinamide on non-motor symptoms in a cohort of patients affected by idiopathic Parkinson's disease.
    Bianchi MLE; Riboldazzi G; Mauri M; Versino M
    Neurol Sci; 2019 Feb; 40(2):275-279. PubMed ID: 30382437
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Long-term Efficacy of Safinamide on Parkinson's Disease Chronic Pain.
    Cattaneo C; Kulisevsky J; Tubazio V; Castellani P
    Adv Ther; 2018 Apr; 35(4):515-522. PubMed ID: 29542008
    [TBL] [Abstract][Full Text] [Related]  

  • 58. [Safinamide from daily clinical practice: first clinical steps].
    Pagonabarraga J; Kulisevsky J
    Rev Neurol; 2017 Nov; 65(10):433-438. PubMed ID: 29130466
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Tremorolytic effects of safinamide in animal models of drug-induced parkinsonian tremor.
    Podurgiel S; Collins-Praino LE; Yohn S; Randall PA; Roach A; Lobianco C; Salamone JD
    Pharmacol Biochem Behav; 2013 Apr; 105():105-11. PubMed ID: 23360954
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Impact of Safinamide on Patient-Reported Outcomes in Parkinson's Disease.
    Espinoza-Vinces C; Villino-Rodríguez R; Atorrasagasti-Villar A; Martí-Andrés G; Luquin MR
    Patient Relat Outcome Meas; 2023; 14():285-295. PubMed ID: 37840836
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 16.